Penalty conversions yield large practical decreases, but robustness and generalizability of result are limited by data quality and sample selection. by Ryan J. Treves (13527735)

nsP4-C483Y or Q192L mutations decrease sensitivity to 4′-FlU. by Peiqi Yin (6533747)

NSC population and proliferation decrease drastically during the second postnatal week of DG development. by Cristina Medina-Menéndez (21800157)

Table of step height. by Jianbo Jia (717814)

Subjects:

The well wall step. by Jianbo Jia (717814)

Subjects:

LBM-based approach using synchronous transformation with a time step of 0.43s, PNGM-based method using asynchronous transformation with a 5s time step, VGA using explicit scheme wi... by Mouad Klai (20818364)

Lens profiles as Ez (orange lines) force was increased and Az and Pz (green lines) forces were decreased. by Ronald A. Schachar (16674576)

Expression of lipid biosynthetic genes is decreased with polyamine depletion. by Yazmin E. Cruz-Pulido (20285238)

Incorporating a social responsibility goal in the prompt causes overleverage in utilities (A) and decreases risk of low ESG rating (B) (Study 3). by Philipp Winder (21615570)

Comparison of diffusion simulations: implicit scheme of the GDE with a 30-second time step (blue line), implicit scheme of the PNGM with α = 0.6 and a 15-second time step (green li... by Mouad Klai (20818364)

The standard deviation of the mean total population abundance was calculated at each time step. by Cyrine Chenaoui (22177098)

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects: